Common Contracts
1 similar null contracts
We have entered into an At Market Issuance Sales Agreement (the “Sale Agreement”) with B. Riley Securities, Inc., BTIG, LLC, and H.C.New York • July 27th, 2021
We are a biotechnology company innovating in the fields of gastrointestinal health and oral biotherapeutics. We apply a multi-omics approach, combining genomics, epigenomics, proteomics, and metabolomics, to the development of a suite of investigational ingestible devices and drug/device combinations designed to provide precise diagnostic sampling and drug delivery solutions. Our vision is to transform healthcare to become more precise and personal by improving the diagnoses of disease and improving patient outcomes through localized treatment with targeted therapies.
